Suppr超能文献

用于药物重新定位的体外筛选。

In vitro screening for drug repositioning.

作者信息

Wilkinson Graeme F, Pritchard Kevin

机构信息

Emerging Innovations, Innovative Medicines, AstraZeneca, Macclesfield, Cheshire, UK

Kevin Pritchard Consulting, uk.linkedin.com/in/kevinpritchardconsulting.

出版信息

J Biomol Screen. 2015 Feb;20(2):167-79. doi: 10.1177/1087057114563024. Epub 2014 Dec 19.

Abstract

Drug repositioning or repurposing has received much coverage in the scientific literature in recent years and has been responsible for the generation of both new intellectual property and investigational new drug submissions. The literature indicates a significant trend toward the use of computational- or informatics-based methods for generating initial repositioning hypotheses, followed by focused assessment of biological activity in phenotypic assays. Another viable method for drug repositioning is in vitro screening of known drugs or drug-like molecules, initially in disease-relevant phenotypic assays, to identify and validate candidates for repositioning. This approach can use large compound libraries or can focus on subsets of known drugs or drug-like molecules. In this short review, we focus on ways to generate and validate repositioning candidates in disease-related in vitro and phenotypic assays, and we discuss specific examples of this approach as applied to a variety of disease areas. We propose that in vitro screens offer several advantages over biochemical or in vivo methods as a starting point for drug repositioning.

摘要

药物重新定位或再利用近年来在科学文献中受到了广泛关注,并且催生了新的知识产权以及 investigational new drug submissions(此处可能有误,推测为“研究性新药申报”)。文献表明,使用基于计算或信息学的方法来生成初始的重新定位假设,随后在表型分析中对生物活性进行重点评估,这是一个显著的趋势。另一种可行的药物重新定位方法是对已知药物或类药物分子进行体外筛选,最初在与疾病相关的表型分析中进行,以识别和验证重新定位的候选药物。这种方法可以使用大型化合物库,也可以专注于已知药物或类药物分子的子集。在这篇简短的综述中,我们重点关注在与疾病相关的体外和表型分析中生成和验证重新定位候选药物的方法,并讨论这种方法应用于各种疾病领域的具体实例。我们认为,作为药物重新定位的起点,体外筛选相对于生化或体内方法具有若干优势。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验